Recommended composition of influenza virus vaccines for use in the 2023 southern hemisphere influenza season

Overview

It is recommended that quadrivalent vaccines for use in the 2023 southern hemisphere influenza season contain the following: 

Egg-based vaccines

• an A/Sydney/5/2021 (H1N1)pdm09-like virus;

• an A/Darwin/9/2021 (H3N2)-like virus;

• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and

• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

Cell culture- or recombinant-based vaccines

• an A/Sydney/5/2021 (H1N1)pdm09-like virus;

• an A/Darwin/6/2021 (H3N2)-like virus;

• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus; and

• a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

It is recommended that trivalent vaccines for use in the 2023 southern hemisphere influenza season contain the following: 

Egg-based vaccines

• an A/Sydney/5/2021 (H1N1)pdm09-like virus;

• an A/Darwin/9/2021 (H3N2)-like virus; and

• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell culture- or recombinant-based vaccines

• an A/Sydney/5/2021 (H1N1)pdm09-like virus;

• an A/Darwin/6/2021 (H3N2)-like virus; and

• a B/Austria/1359417/2021 (B/Victoria lineage)-like virus